Literature DB >> 17468191

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Anna Stern1, Gail A Laughlin, Jaclyn Bergstrom, Elizabeth Barrett-Connor.   

Abstract

OBJECTIVE: The role of osteoprotegerin (OPG) and its receptor activator of nuclear factor kappaB legend (RANKL) in the regulation of bone in humans remain unclear. We examined the sex-specific associations of serum OPG, RANKL, and their ratio with bone mineral density (BMD) in older adults.
DESIGN: Participants were 681 community-dwelling adults, ages 45-90 years, who had serum OPG and RANKL measured and bone density scans in 1988-1991, with follow-up scans 5 and/or 10 years later.
METHODS: Analyses were sex-specific; women using and not using estrogen were evaluated separately. Cross-sectional analyses used multivariable regression models; longitudinal analyses used repeated measures mixed effects models.
RESULTS: In cross-sectional analyses, age- and weight-adjusted serum OPG levels were significantly positively associated with BMD at the lumbar spine in men, and at the femoral neck, total hip, and lumbar spine in women using estrogen, but not in non-users of estrogen. RANKL concentrations were significantly and inversely associated with BMD in men only, and at the total hip. Neither OPG nor RANKL was significantly associated with bone loss. Results for the RANKL/OPG ratio were the same as those for RANKL alone.
CONCLUSIONS: These results suggest a modulatory effect of both endogenous and exogenous sex hormones on the biologic interaction of OPG, RANKL, and bone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468191      PMCID: PMC2642656          DOI: 10.1530/EJE-06-0753

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  40 in total

1.  17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha.

Authors:  M Saika; D Inoue; S Kido; T Matsumoto
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

Review 2.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

3.  Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study.

Authors:  Simerjot K Jassal; Denise von Muhlen; Elizabeth Barrett-Connor
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

Review 4.  Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Authors:  L C Hofbauer; A E Heufelder
Journal:  J Mol Med (Berl)       Date:  2001-06       Impact factor: 4.599

5.  Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges.

Authors:  H A Makhluf; S M Mueller; S Mizuno; J Glowacki
Journal:  Biochem Biophys Res Commun       Date:  2000-02-24       Impact factor: 3.575

6.  Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.

Authors:  P Szulc; L C Hofbauer; A E Heufelder; S Roth; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

7.  Correlates of osteoprotegerin levels in women and men.

Authors:  S Khosla; H M Arrighi; L J Melton; E J Atkinson; W M O'Fallon; C Dunstan; B L Riggs
Journal:  Osteoporos Int       Date:  2002-05       Impact factor: 4.507

8.  Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

Authors:  A Rogers; G Saleh; R A Hannon; D Greenfield; R Eastell
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

9.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype.

Authors:  Tim Cundy; Madhuri Hegde; Dorit Naot; Belinda Chong; Alan King; Robyn Wallace; John Mulley; Donald R Love; Joerg Seidel; Matthew Fawkner; Tatjana Banovic; Karen E Callon; Andrew B Grey; Ian R Reid; Catherine A Middleton-Hardie; Jillian Cornish
Journal:  Hum Mol Genet       Date:  2002-09-01       Impact factor: 6.150

10.  Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells.

Authors:  Lorenz C Hofbauer; Kevin C Hicok; David Chen; Sundeep Khosla
Journal:  Eur J Endocrinol       Date:  2002-08       Impact factor: 6.664

View more
  37 in total

Review 1.  Genetic epidemiology of age-related osteoporosis and its clinical applications.

Authors:  Ching-Lung Cheung; Su-Mei Xiao; Annie W C Kung
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

2.  The Effects of Dietary Supplements of Calcium, Vitamin D and Estrogen Hormone on Serum Levels of OPG and RANKL Cytokines and their Relationship with Increased Bone Density in Rats.

Authors:  Fatemeh Piri; Afra Khosravi; Ardeshir Moayeri; Ayat Moradipour; Siamak Derakhshan
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

4.  Oxytocin levels are lower in premenopausal women with type 1 diabetes mellitus compared with matched controls.

Authors:  Amber S Kujath; Lauretta Quinn; Mary E Elliott; Krista A Varady; Tamara J LeCaire; C Sue Carter; Kirstie K Danielson
Journal:  Diabetes Metab Res Rev       Date:  2014-09-03       Impact factor: 4.876

5.  Genetic Risk Scores Implicated in Adult Bone Fragility Associate With Pediatric Bone Density.

Authors:  Jonathan A Mitchell; Alessandra Chesi; Okan Elci; Shana E McCormack; Sani M Roy; Heidi J Kalkwarf; Joan M Lappe; Vicente Gilsanz; Sharon E Oberfield; John A Shepherd; Andrea Kelly; Struan Fa Grant; Babette S Zemel
Journal:  J Bone Miner Res       Date:  2015-12-14       Impact factor: 6.741

6.  Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle.

Authors:  Bruno Mozzanega; Salvatore Gizzo; Daniela Bernardi; Luigi Salmaso; Tito Silvio Patrelli; Roberto Mioni; Livio Finos; Giovanni Battista Nardelli
Journal:  J Bone Miner Metab       Date:  2013-03-12       Impact factor: 2.626

7.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

8.  Elevated ferritin and circulating osteoprotegerin levels as independent predictors of hip fracture in postmenopausal women admitted for fragility fracture: time for new screening strategies?

Authors:  Y Lipovetzki; G Zandman-Goddard; Z Feldbrin; M Shargorodsky
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Vitamin K, circulating cytokines, and bone mineral density in older men and women.

Authors:  M Kyla Shea; Gerard E Dallal; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Caren M Gundberg; James W Peterson; Sarah L Booth
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

10.  Immune changes in post-menopausal osteoporosis: the Immunos study.

Authors:  V Breuil; M Ticchioni; J Testa; C H Roux; P Ferrari; J P Breittmayer; C Albert-Sabonnadière; J Durant; F De Perreti; A Bernard; L Euller-Ziegler; G F Carle
Journal:  Osteoporos Int       Date:  2009-10-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.